OEP Group’s biotech subsidiary Orient Pharma was listed on the Taipei Exchange on the 21st. Chairman Tsai, Cheng-Hung stated that the company will continue to capitalize on patent expirations and market gaps, leveraging its core technology platforms to build a differentiated product portfolio and enhance global competitiveness.

Focusing on 505(b)(2) new drugs and niche generics in high-demand areas such as central nervous system, cardiovascular, and diabetes treatments, Orient Pharma’s most closely watched product is Methydur, a new drug for ADHD (Attention Deficit Hyperactivity Disorder). Methydur has already received marketing approval and National Health Insurance reimbursement in Taiwan. The company is now accelerating expansion into China, the U.S., Europe, and Japan, while simultaneously filing new drug applications (NDA) in Southeast Asian countries including Hong Kong, Singapore, Malaysia, the Philippines, and Vietnam, underscoring its strong international ambitions.

In addition, Tonvasca, a new combination drug for lipid-lowering, will soon be submitted for approval in Australia and Southeast Asia, bringing new momentum to operations. Orient Pharma has already secured over 50 marketing approvals, with a sales network spanning 12 countries across five continents. In Taiwan, its products have entered 23 medical centers, 86 regional hospitals, and more than 4,600 clinics, establishing a comprehensive distribution channel.

On the international collaboration front, Orient Pharma has established deep partnerships with global pharmaceutical companies through a licensing-out model, and expects to generate milestone payments and royalties from its ADHD and anti-infective drugs, ensuring a stable cash flow.

To address raw material price volatility and capacity challenges, the company is enhancing operational efficiency and implementing cost-control strategies to strengthen overall competitiveness. Measures include optimizing production scheduling, scaling up manufacturing batch sizes to achieve economies of scale, and introducing second-source raw material procurement to ensure stable supply while balancing cost efficiency.

Furthermore, Orient Pharma is maximizing resource utilization by offering CDMO services to activate idle production capacity. Moving forward, it plans to allocate dedicated equipment according to dosage form characteristics to support large-scale production needs and further reduce manufacturing costs.

Tsai emphasized that Orient Pharma will continue to focus on high-demand therapeutic areas such as central nervous system, cardiovascular, and diabetes, while leveraging its core technology platforms—Semi-solid Multiple Release Technology (SMRT), Multiple Unit Pellet System (MUPS), and Osmotic Release Oral System (OROS)—to develop 505(b)(2) new drugs and niche generics with strong clinical value.

Resource: 友霖拚打國際局 ADHD新藥加速擴海外版圖